Tomaz Kocjan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1728103/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
2	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	2.7	97
3	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
4	A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones, 2015, 14, 81-90.	1.9	67
5	Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT. European Journal of Surgical Oncology, 2017, 43, 133-137.	1.0	65
6	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	3.6	65
7	Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. Journal of Ovarian Research, 2015, 8, 32.	3.0	55
8	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	11.4	55
9	¹⁸ F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands. Journal of Nuclear Medicine, 2020, 61, 577-583.	5.0	50
10	Optimal scan time for evaluation of parathyroid adenoma with [¹⁸ F]-fluorocholine PET/CT. Radiology and Oncology, 2015, 49, 327-333.	1.7	44
11	A New Clinical Prediction Criterion Accurately Determines A Subset of Patients with Bilateral Primary Aldosteronism Before Adrenal Venous Sampling. Endocrine Practice, 2016, 22, 587-594.	2.1	33
12	Changes in Th1/Th2 cytokine balance in Graves' desease. Pflugers Archiv European Journal of Physiology, 2000, 440, R094-R095.	2.8	26
13	Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	3.6	25
14	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
15	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	3.6	18
16	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	2.7	13
17	Changes in Th1/Th2 cytokine balance in Graves' disease. Pflugers Archiv European Journal of Physiology, 2000, 440, R94-5.	2.8	13
18	Methimazole upregulates T-cell-derived cytokines without improving the existing Th1/Th2 imbalance in Graves' disease. Journal of Endocrinological Investigation, 2004, 27, 302-307.	3.3	10

Tomaz Kocjan

#	Article	IF	CITATIONS
19	Adrenal vein sampling for primary aldosteronism: a 15-year national referral center experience. Radiology and Oncology, 2020, 54, 409-418.	1.7	9
20	Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan. Frontiers in Endocrinology, 2022, 13, 816426.	3.5	8
21	Outcome parameters in orthogeriatric co‑management– aÂmini-review. Wiener Klinische Wochenschrift, 2016, 128, 492-496.	1.9	7
22	Adrenal crisis after first infusion of zoledronic acid: a case report. Osteoporosis International, 2018, 29, 1675-1678.	3.1	7
23	Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis. Endocrine Practice, 2021, 27, 941-947.	2.1	7
24	Validation of three novel clinical prediction tools for primary aldosteronism subtyping. Endocrine Connections, 2022, 11, .	1.9	6
25	Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study. Endocrine Connections, 2021, 10, 637-645.	1.9	5
26	Limited diagnostic utility of partially successful adrenal vein sampling for primary aldosteronism subtyping. Endokrynologia Polska, 2021, 72, 293-300.	1.0	5
27	Treatment of osteoporosis with teriparatide: The Slovenian experience. Open Medicine (Poland), 2021, 16, 1544-1551.	1.3	2
28	Patients with Central Hypothyroidism are Less Sufficiently Treated with Levothyroxine than Patients with Primary Hypothyroidism. Experimental and Clinical Endocrinology and Diabetes, 2021, , .	1.2	1